DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 10 — - 8 Jim Cramer - 7 Jim - 7 Jim Cramer's - 7 Zepbound - 4 Eli Lilly's - 4 Lilly's - 4
Top related locs:
U.S China Mounjaro Trulicity Indianapolis , Indiana Provo , Utah Danish California
Top related orgs:
CNBC - 8 U.S - 6 FDA - 5 Novo Nordisk - 5 Getty - 5 Bloomberg - 4 Service - 3 Business - 3

Search resuls for: "Zepbound —"


11 mentions found


☆ A millennial couldn't afford the Mounjaro weight-loss drug so he started secretly working 2 remote jobs. He's on track to make $166,000 this year and says he's lost 45 pounds.
  + stars: | 2024-05-01 | by ( Jacob Zinkula | ) www.businessinsider.com   time to read: +6 min
A millennial in California is secretly working a second remote job so he can afford weight-loss drugs. AdvertisementLast August, George decided he wanted to try to work a second remote job — and not tell his employers he was job juggling. He was able to afford Mounjaro and said he's dropped 45 pounds — from 220 lbs to 175 lbs — since he started taking it in October. AdvertisementAfter a roughly monthlong search, he started his second job and was able to afford Mounjaro. Are you working multiple remote jobs at the same time and willing to discuss details about your pay and schedule?
Persons: Zepbound, —, George, Eli Lilly, he's, George hasn't, it's Organizations: Service, FDA, Nordisk's Ozempic, Business Locations: California, Mounjaro
☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
  + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.
Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S
☆ These were our 4 best — and 4 worst — portfolio stocks in the first quarter
  + stars: | 2024-03-29 | by ( Morgan Chittum | ) www.cnbc.com   time to read: +9 min
The winners NVDA YTD mountain Nvidia (NVDA) year-to-date performance Nvidia came in No. META YTD mountain Meta Platforms (META) year-to-date performance Meta Platforms climbed 37.2% in the first quarter, coming in at second place within the portfolio. The laggards AAPL YTD mountain Apple (AAPL) year-to-date performance Apple suffered the most first-quarter losses in the portfolio, slumping 10.9% during the period. FL YTD mountain Foot Locker (FL) year-to-date performance Shares of Foot Locker declined 8.5% in the first quarter, making the sneaker retailer the second-worst-performing stock in the portfolio. PANW YTD mountain Palo Alto Networks (PANW) year-to-date performance Palo Alto Networks stock fell 3.7% during the first quarter, rounding out No.
Persons: Dow, chipmaker, It's, Instagram, Meta's, Jim Cramer, Walt Disney, Nelson Peltz, Jim, Peltz's Trian, Eli Lilly, LLY, Eli Lilly's, Apple, Locker's, Locker, Jim Cramer's, Jensen Huang, Ann Wang Organizations: Dow Jones Industrial, Nasdaq, Nvidia, Facebook, Wall, DIS, Walt Disney, Peltz, Peltz's Trian Partners, Disney, U.S, Department of, Apple, Evercore ISI, Citigroup, Nike, Starbucks, Palo Alto Networks, Palo, Jim Cramer's Charitable, CNBC Locations: China, Seattle, U.S, Palo, Taipei, Taiwan
☆ Eli Lilly climbs on win for rival weight-loss drug, and we still feel good about Abbott Labs
  + stars: | 2024-03-28 | by ( Jeff Marks | ) www.cnbc.com   time to read: +4 min
Abbott update : Shares of Abbott Laboratories were slightly higher Thursday, on pace for their third straight day of gains. The embattled cosmetics company was the top-performing Club stock in Thursday's session, boosted by an upgrade at Bank of America . As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Eli Lilly, Wegovy, Abbott, Louis, Jim, Reckitt's Mead Johnson, Mead, Johnson, Stanley Black, Decker, Estee Lauder, Lauder, there's, Jim Cramer's, AJ Mast Organizations: CNBC, Stocks, Bloomberg, Amazon Pharmacy, Rite, Abbott Laboratories, Abbott, NEC, Home, U.S, Bank of America, Jim Cramer's Charitable, Getty Locations: U.S, St, Illinois, China, Indianapolis , Indiana
☆ Oprah has left WeightWatchers, sending stocks spiraling and spelling doom for the diet of our foremothers
  + stars: | 2024-02-29 | by ( Mia De Graaf | Rachel Hosie | ) www.businessinsider.com   time to read: +7 min
Oprah Winfrey will not seek reelection to the board of WW International, known as WeightWatchers. It was a surprising time to jump on board — WeightWatchers had been shedding users, and its stock price was dwindling. AdvertisementDespite not naming the brand, there was an immediate spike in demand for GLP-1 medications — the popular new class of weight-loss drugs. That same day, WW added a weight-loss drug arm to its business, acquiring Sequence, a service that provides weight-loss drugs. AdvertisementLong-term, WW needs to find a new identityOver time, WW will benefit from being a purveyor of hard-to-access weight-loss drugs.
Persons: Oprah Winfrey, —, Oprah giveth, Oprah taketh, maven, Winfrey, — WeightWatchers, Axios, Oprah, Forbes, Craig, Alex Fuhrman, Winfrey's, We're, Atkins Organizations: WW International, Service, SEC, Guardian, People Magazine, MarketWatch, Mayo Clinic, Business, Smithsonian's National Museum of, CNBC, Slate Locations: GLP, WeightWatchers
☆ Here's how I see the Fed's rate-cut dilemma playing out — and 5 more themes for 2024
  + stars: | 2024-02-25 | by ( Jim Cramer | ) www.cnbc.com   time to read: +7 min
Here's why: The conversion from three or four cuts to two to one to no cuts won't happen overnight. It won't be a headlong rush out of the stock market. As long as enough people think rate cuts are going to occur, there won't be torrent of money going to the sidelines. What else could influence our thinking for 2024 besides this rate-cut dilemma? As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
Persons: Jim Cramer's, Nixon, Goldwater, John Ellis, Steve Schwarzman, Blackstone, There's, we're, It's, Estee Lauder, Eaton, Ingersoll Rand, Nucor, Eli Lilly, —, Zepbound, aren't, Jim Cramer, Jim Organizations: CNBC, Club, Fed, Federal Reserve, U.S, Army, U.S . Army, Republican, Federal Trade Commission, Microsoft, Activision, Wynn Resorts, Apple, Palo Alto Networks, Nvidia, GOP, That's, Caterpillar, it's Novo Nordisk, Jim Cramer's Charitable Locations: Vietnam, Wisconsin , Michigan, Pennsylvania, North Carolina , Georgia, Arizona, Nevada, China
☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
  + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +10 min
Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.
Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah
☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
  + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.
Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah
☆ Healthcare companies are promising to help patients quit Wegovy. There's just one problem with that.
  + stars: | 2023-12-19 | by ( ) www.businessinsider.com   time to read: +11 min
Inkinen said Virta can help patients quit GLP-1 drugs and keep weight off by adjusting the foods they eat to help them feel full, similar to how the drugs reduce feelings of hunger. About 82% of patients taking Wegovy experience gastrointestinal issues like nausea and diarrhea. WeightWatchers didn't provide Business Insider with published data to support its claims that it can help people keep weight off after quitting weight-loss drugs. AdvertisementHe also advises the weight-loss startup Calibrate, which tapers some patients off GLP-1 drugs after they reach a certain body-mass index. GLP-1 drugs also slash the risk of heart attacks, strokes, and cardiac-related death.
Persons: —, Michael Albert, aren't, Sami Inkinen, Inkinen, Virta, Michael Siluk, Noom's, Linda Anegawa, Carolina Rudah, tirzepatide, Mounjaro, Zepbound —, Eli Lilly, Ozempic, Wegovy, Randy Seeley, Seeley, Robyn Phelps, it's, Robert Kushner, Kushner, Florian Gaertner, It's, Albert, Lisa, she's, I'm Organizations: Service, Business, FDA, Virta, Getty, Nordisk, Michigan Nutrition Obesity Research, University of Michigan, Novo Nordisk, Northwestern University Locations: Denver, Michigan
☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
  + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +5 min
In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.
Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana
☆ Eli Lilly and more: Strategist names 5 stocks set for 'significant' earnings growth
  + stars: | 2023-11-10 | by ( Amala Balakrishner | ) www.cnbc.com   time to read: +4 min
Rising rates and the possibility of a recession on the horizon have created a "mixed picture" for equity markets, according to one strategist — but several companies can look forward to markedly stronger earnings growth in the next year. "But, if you're looking for significant earnings expansion, I suspect, at a market level, that's probably less likely. The earnings growth rate for the S & P 500 was 3.7% year-on-year – the first quarter with year-on-year growth since the third quarter of 2022, the data showed. "What Eli Lilly is going to do with their weight loss drug is not dependent on whether the rates are 5.2% or 4.8%. "People didn't really talk about [Adobe] — everyone assumed that they were going to be a loser from AI," he said.
Persons: —, they're, Rahul Ghosh, Rowe Price, Ghosh, Eli Lilly, Powell, Software Ghosh, — CNBC's Annika Kim Constantino Organizations: Healthcare Healthcare, UnitedHealth Group, Fellow, Food and Drug Administration, Software, Adobe Creative, Adobe Express
0 next >>
Total: 11